Cardio3 BioSciences appoints Dr. Warren Sherman as Chief Medical Officer
Cardio3 BioSciences (C3BS) announced the appointment of Dr. Warren Sherman as Chief Medical Officer, effective as of 1 November 2014. In this new role, Dr. Sherman will leverage his deep expertise in the cardiovascular and cell therapy fields to support the continued development of Cardio3 BioSciences’ product pipeline, both in cell therapies and cardiovascular diseases.
Dr. Sherman is a American interventional cardiologist with more than 30 years’ experience in the field of cardiology, with a focus in cell-based therapies for treating patients post myocardial infarction and with heart failure.
Before joining Cardio3 BioSciences as Chief Medical Officer, Dr. Sherman was at the Columbia University Medical Center in New York, where he served in a number of capacities, including: Interventional Cardiologist at Columbia University Medical Center/NewYork-Presbyterian Hospital; Director of Stem Cell Research and Regenerative Medicine at the Center for Interventional Vascular Therapy; and Associate Professor of Medicine at Columbia University College of Physicians and Surgeons.
Dr. Sherman is also the founder of the Cardiovascular Research Foundation’s International Conference on Cell Therapy for Cardiovascular Disease (IC3D).
Dr. Sherman received his Bachelors degree from the Massachusetts Institute of Technology, medical degree from the State University of New York Upstate Medical School in Syracuse, and his fellowship training at Oregon Health Sciences University, in Portland, Oregon. He is certified by the American Board of Internal Medicine in Cardiology and Interventional Cardiology, and serves as an advisor to a multitude of government organizations, societies and industries.
Other news from the department people
